Stage III non-small cell lung cancer
Conditions
Interventions
None listed
Sponsors
AstraZeneca K.K
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: [1st cohort] 1.Patients giving written informed consent to participate in this study (for patients who have died or been lost to follow up, the instructions of the ERB in each medical institution [e.g., general consent and opt-out] should be followed) 2.Male or female patients aged 20 years or older at the time of diagnosis of stage III NSCLC 3.Patients diagnosed with unresectable stage III NSCLC between January 1 2013 and December 31 2015 4.Patients who were received curative chemoradiotherapy including platinum (the patients diagnosed as unresectable who were received the salvage surgery after chemoradiotherapy are eligible) [2nd cohort] 5.Patients giving written informed consent to participate in this study (for patients who have died or been lost to follow up, the instructions of the ERB in each medical institution [e.g., general consent and opt-out] should be followed) 6.Male or female patients aged 20 years or older at the time of diagnosis of stage III NSCLC 7.Patients diagnosed with stage III NSCLC between January 1 2013 and December 31 2014 8.Patients who were received any aggressive treatment without supportive care or no treatment
Exclusion criteria
Exclusion criteria: 1. Patients receiving unapproved drugs for the treatment of NSCLC at the initiation of this study 2. Patients who are regarded as inappropriate to participate in the study by the primary investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| [1st cohort] 1.To estimate OS in the overall cohort population [2nd cohort] 2.To estimate OS in the overall cohort population | — |
Secondary
| Measure | Time frame |
|---|---|
| [1st cohort] 1.To estimate PFS in the overall cohort populations and OS and PFS by treatment regimen 2.To estimate ORR and TTDM in the overall cohort populations and by treatment regimen 3.To evaluate safety profile of treatment for patients with stage III NSCLC in terms of treatment-related adverse events including pneumonitis/radiation pneumonitis 4.To summarize treatment outcomes stratified by clinical characteristics [2nd cohort] 5.To summarize the patient characteristics at initial diagnosis in overall cohort population and in type of initial treatments 6.To estimate OS, PFS, and DFS (in case of surgery) in type of initial treatment 7.To estimate ORR and TTDM in type of initial treatment, without surgery 8.To evaluate safety profile of treatment for patients with stage III NSCLC in terms of treatment-related adverse events including pneumonitis/radiation pneumonitis 9.To summarize treatment outcomes stratified by clinical characteristics | — |
Countries
Japan
Contacts
Public ContactSatomi Kohata
A2 Healthcare Corporation Clinical Research Department
Outcome results
None listed